Drug
Paricalcitol clinical trials
Also written Zemplar and ABT-358.
- studies test it
- 90
- open now
- 2
- in phase 3
- 20
- first study started
- 2002
Keep track of what changes. Save the paricalcitol studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
90 studies that test it; most in 2009 (14)
| Year | Studies |
|---|---|
| 2002 | 5 |
| 2003 | 3 |
| 2004 | 4 |
| 2005 | 3 |
| 2006 | 5 |
| 2007 | 6 |
| 2008 | 8 |
| 2009 | 14 |
| 2010 | 10 |
| 2011 | 4 |
| 2012 | 7 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 9
- Phase 2
- 21
- Phase 3
- 20
- Phase 4
- 27
- No phase
- 11
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 33 · Other 57
Abbott (21) · AbbVie (prior sponsor, Abbott) (5) · Abramson Cancer Center at Penn Medicine (3) · Wake Forest University Health Sciences (3) · Cedars-Sinai Medical Center (2) · HonorHealth Research Institute (2) · Washington University School of Medicine (2) · Mario Negri Institute for Pharmacological Research (2)
Often tested with
Tested in the same studies.
Calcitriol (6) · Gemcitabine (3) · 1 alpha-hydroxyergocalciferol (3) · Hydroxychloroquine (2) · Albumin-Bound Paclitaxel (2) · Paclitaxel (2) · Cholecalciferol (2) · Losartan (1)
Studies
Open first, then newest update. How each study uses paricalcitol is read from its arms, and is right about nine times in ten.
Testing it · 90
- Paricalcitol Versus Pirfenidone for Improving Surgical Resectability in Patients With Peritoneal CancerNot yet recruitingPhase 2Patrick Wagner, MD, FACSNCT07856914Written as Paricalcitol
- The Impact of Selective Vitamin D Receptor Activation on Clinical Outcomes in Septic PatientsNot yet recruitingNot applicableUniversity of Split, School of MedicineNCT06209268Written as Paricalcitol injection
- A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitisActive, not recruitingEarly Phase 1Cedars-Sinai Medical CenterNCT05664880Written as Paricalcitol
- A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)TerminatedPhase 3AbbVieNCT04064827Written as Paricalcitol
- PHL Treatment in Pancreatic CancerActive, not recruitingEarly Phase 1Fox Chase Cancer CenterNCT05365893Written as Paricalcitol, Hydroxychloroquine, Losartan
- Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)CompletedPhase 2HonorHealth Research InstituteNCT03415854Written as Paricalcitol (Zemplar)
- Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic CancerCompletedPhase 2Emory UniversityNCT04524702Written as Paricalcitol
- Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal AdenocarcinomaCompletedPhase 2HonorHealth Research InstituteNCT02754726Written as Paricalcitol
- A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic CancerCompletedPhase 1Abramson Cancer Center at Penn MedicineNCT02030860Written as Paricalcitol
- Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic CancerTerminatedPhase 1Dana-Farber Cancer InstituteNCT03520790Written as Paricalcitol
- Paricalcitol Improves Anemia of InflammationTerminatedPhase 4Hospital Son EspasesNCT02876211Written as Paricalcitol
- A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic CancerTerminatedEarly Phase 1Abramson Cancer Center at Penn MedicineNCT03519308Written as Paricalcitol
- Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic CancerCompletedPhase 2Cancer Trials IrelandNCT04617067Written as Paricalcitol
- Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. ParicalcitolTerminatedPhase 4Winthrop University HospitalNCT01725113Written as Paricalcitol
- A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic CancerCompletedPhase 2Translational Genomics Research InstituteNCT03331562Written as paricalcitol
- Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based TherapyCompletedPhase 1Washington University School of MedicineNCT03883919Written as Paricalcitol
- A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic CancerTerminatedPhase 1Abramson Cancer Center at Penn MedicineNCT03300921Written as Paricalcitol
- A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary HyperparathyroidismStatus unknownPhase 3Chengdu Suncadia Medicine Co., Ltd.NCT04994080Written as Paricalcitol
- A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant PatientsCompletedPhase 4AbbVie (prior sponsor, Abbott)NCT01506947Written as Paricalcitol
- Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic RicketsCompletedPhase 3Yale UniversityNCT00417612Written as Paricalcitol
See all 90 studies that test paricalcitol →
Given in every arm · 3 — paricalcitol is usual care beside what is tested
- Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal AdenocarcinomaCompletedPhase 2Barts & The London NHS TrustNCT04054362Written as Paricalcitol
- Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by SurgeryCompletedPhase 1M.D. Anderson Cancer CenterNCT02930902Written as Paricalcitol
- Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002CompletedPhase 3OPKO Health, Inc.NCT02282813Written as Paricalcitol
As the comparator · 1 — what is tested is compared with paricalcitol
Codes
What other systems call paricalcitol · ClinicalTrials.gg INT003762
- MeSH (NLM) C084656paricalcitolConfirmed NLM, Wikidata
- UNII (FDA) 6702D36OG5PARICALCITOLConfirmed FDA, NLM, Wikidata
- RxNorm 73710Confirmed FDA, Wikidata
- Wikidata Q155746paricalcitolConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C38693ParicalcitolOne source FDA
- DrugBank DB00910One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C084656 | paricalcitol | Confirmed NLM, Wikidata |
| UNII (FDA) | 6702D36OG5 | PARICALCITOL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 73710 | — | Confirmed FDA, Wikidata |
| Wikidata | Q155746 | paricalcitol | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C38693 | Paricalcitol | One source FDA |
| DrugBank | DB00910 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.